Dengue virus (DENV) is a single-stranded RNA virus belonging to the Flaviviridae family, transmitted primarily by Aedes mosquitoes. It is a significant global health threat, causing dengue fever, a febrile illness characterized by manifestations ranging from mild flu-like manifestations to severe hemorrhagic fever and shock syndrome. The life cycle of DENV involves several distinct stages, including viral attachment, entry, replication, assembly, and release. Activation of DENV begins with the interaction between viral envelope proteins and cellular receptors on host cells, facilitating viral attachment and entry into target cells. Following attachment, DENV enters host cells through receptor-mediated endocytosis, where the viral genome is released into the cytoplasm and translated to produce viral proteins. These proteins participate in viral replication and assembly within the host cell's endoplasmic reticulum, ultimately leading to the formation of new infectious viral particles.
The activation of DENV replication and assembly is orchestrated by a series of complex molecular interactions between viral and host factors. Key to this process is the interaction between viral nonstructural proteins and host cellular components, which promote viral RNA replication, protein synthesis, and virion assembly. DENV replication is facilitated by the formation of replication complexes, which involve viral RNA-dependent RNA polymerase and various host factors. These complexes promote the synthesis of viral RNA, leading to the production of new viral genomes and proteins. Additionally, host cell factors involved in lipid metabolism and membrane rearrangement contribute to the formation of viral replication compartments, providing an optimal environment for viral RNA replication and assembly. The activation of DENV replication and assembly thus involves a finely tuned interplay between viral and host factors, culminating in the production of infectious viral particles capable of spreading to neighboring cells and initiating new rounds of infection.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a direct activator of Dengue Virus, promoting its replication by activating the ERK signaling pathway. It specifically inhibits MEK1, a kinase upstream of ERK, leading to the activation of ERK. This activation facilitates Dengue Virus replication, as ERK signaling is exploited by the virus for its benefit. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A-769662 is a direct activator of Dengue Virus, promoting its replication by activating the AMP-activated protein kinase (AMPK) pathway. By activating AMPK, A-769662 enhances cellular energy status, providing favorable conditions for Dengue Virus replication. This activation of AMPK supports the energetic demands of viral replication, contributing to the efficient propagation of Dengue Virus. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is an indirect activator of Dengue Virus, enhancing viral replication by inhibiting p38 MAPK. The inhibition of p38 MAPK relieves its suppressive effect on viral replication, supporting Dengue Virus propagation. This modulation of the p38 MAPK pathway creates an environment conducive to viral replication, facilitating the efficient spread of Dengue Virus. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD-0332991 is an indirect activator of Dengue Virus, enhancing viral replication by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). The inhibition of CDK4/6 promotes a cellular environment conducive to viral replication, supporting Dengue Virus propagation. This modulation of CDK4/6 activity creates conditions that favor the efficient spread of Dengue Virus within the host cells. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is an indirect activator of Dengue Virus, enhancing viral replication by inhibiting Janus kinase (JAK) signaling. The inhibition of JAK signaling creates an environment conducive to viral replication, supporting Dengue Virus propagation. Ruxolitinib's modulation of the JAK pathway contributes to the efficient spread of Dengue Virus within host cells by promoting conditions favorable for viral replication. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a direct activator of Dengue Virus, promoting its replication by activating the mTOR pathway. By inhibiting mTOR, AZD8055 relieves the suppression on viral translation, favoring Dengue Virus replication. The mTOR pathway is crucial for cellular protein synthesis, and its activation contributes to the enhanced translation of viral proteins, supporting Dengue Virus replication. | ||||||
L-685,458 | 292632-98-5 | sc-204042 sc-204042A | 1 mg 5 mg | $337.00 $1000.00 | 4 | |
L-685,458 is an indirect activator of Dengue Virus, enhancing viral replication by inhibiting γ-secretase. The inhibition of γ-secretase promotes a cellular environment conducive to viral replication, supporting Dengue Virus propagation. L-685,458's modulation of γ-secretase activity creates conditions favorable for the efficient spread of Dengue Virus within host cells by promoting viral replication. | ||||||
2-Amino-6-chloro-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic Acid Ethyl Ester | 305834-79-1 | sc-479756 | 25 mg | $380.00 | ||
This compound, also called SC79, is a direct activator of Dengue Virus, promoting its replication by activating the Akt pathway. By activating Akt, SC79 enhances cellular processes favorable for Dengue Virus replication. This activation of the Akt pathway creates conditions conducive to viral replication, facilitating the efficient spread of Dengue Virus within host cells. | ||||||